Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIADEM: Durvalumab in Advanced Pretreated Malignant Pleural Mesothelioma
2016-000617-67Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Oct 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in pleural mesothelioma, sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Progression-free survival at 16 weeks. Started Oct 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2016-000617-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000617-67.